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Abstract
Background: Collagen-containing leukocytes (CD45
+Col-I
+) accumulate in diseased and fibrotic tissues. However,
the precise identity of these cells and whether injury is required for their recruitment remain unknown. Using a
murine model of pulmonary fibrosis in which an inducible, bioactive form of the human transforming growth
factor (TGF)-b1 gene is targeted to the lung, we characterized the cell surface phenotype of collagen-containing
CD45
+ cells in the lung and tested the hypothesis that apoptotic cell death responses are essential to the
accumulation of CD45
+Col-I
+ cells.
Results: Our studies demonstrate that CD45
+Col-I
+ cells appearing in the TGF-b1-exposed murine lung express
markers of the monocyte lineage. Inhibition of apoptosis via pharmacological caspase blockade led to a significant
reduction in CD45
+Col-I
+ cells, which appear to accumulate independently of alternatively activated macrophages.
There are also increased levels of apoptosis and greater numbers of CD45
+Col-I
+ in the lung tissue of patients with
two distinct forms of fibrotic lung disease, idiopathic pulmonary fibrosis and connective tissue disease-related
interstitial lung disease, when compared to lung from healthy normal controls. These findings are accompanied by
an increase in collagen production in cultured monocytes obtained from subjects with fibrotic lung disease.
Treatment of these cultured cells with the caspase inhibitor carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-
fluoromethylketone (Z-VAD/fmk) reduces both apoptosis and collagen production in all subjects.
Conclusions: Interventions that prevent collagen production by monocytes via modulation of caspase activation
and of apoptosis may be ameliorative in monocyte-associated, TGF-b1-driven processes such as pulmonary fibrosis.
Background
The CD14
+ fraction of peripheral blood contains hetero-
geneous monocyte progenitors with important roles in
tissue injury and repair [1]. A subpopulation of mono-
cytes differentiates into fibrocytes by acquiring a fibro-
blast-like morphology, gaining expression of collagen I
and CD34 while losing CD14 expression [2]. Fibrocytes
accumulate in transforming growth factor (TGF)-b1-
e x p o s e dt i s s u e s[ 3 ]a n da r ea s s o c i a t e dw i t ha na r r a yo f
fibrosing disorders including asthma, pulmonary fibrosis,
and scleroderma [4-6]. Due to the considerable
variability in methods used to identify these cells, con-
troversy exists as to their true phenotype [7,8] though
the presence of fibrocytes in several forms of fibrosis is
now well established. The mechanism(s) through which
fibrocytes and related CD45
+ collagen (Col)-I
+ cells con-
tribute to fibrosis remain unclear, but may be related to
immunological regulation of effector cell phenotypes [9]
as well as direct production of extracellular matrix pro-
teins or a-smooth muscle actin (SMA) production
[10,11]. This phenotype is specialized for the character-
istics that might be required for repair. However, while
the administration of human fibrocytes to severe com-
bined immunodeficiency (SCID) mice requires coadmi-
nistration of bleomycin to result in pathology [12],
requirement for injury in the accumulation of CD45
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+ in the TGF-b1-exposed murine lung has not
been shown.
Pulmonary fibrosis is a progressive and often fatal dis-
ease for which there are no effective therapies. The cur-
rent paradigm of pulmonary fibrosis pathogenesis
includes recurrent epithelialc e l ld e a t hr e s p o n s e sw i t h
subsequent recruitment of a monocyte-derived inflam-
matory infiltrate and the eventual development of myofi-
broblast activation [13]. These events are believed to be
heavily influenced by TGF-b1 [14-17]. While the precise
type of injury initiating these events remains unknown,
substantial evidence supports a role for apoptosis as a
contributing factor [18-20]. Elevations in circulating and/
or tissue CD45
+Col-I
+ cells have are seen in a broad
array of fibrosing lung diseases including idiopathic pul-
monary fibrosis (IPF) [4], asthma [5], post-transplant
bronchiolitis obliterans syndrome [21], and scleroderma
[6]. Many of these diseases are associated with abnormal-
ities in apoptosis [19,22,23]; however, a relationship
between CD45
+Col-I
+ cells, specifically fibrocytes, and
apoptosis has not been previously assessed.
We have recently shown that transgenic overexpres-
sion of TGF-b1 results in the accumulation of cells that
coexpress CD45 and Col-Ia1 [24]. However, the cell
surface phenotype of these cells remains unexplored and
the local events initiating TGF-b1-induced accumulation
of CD45
+Col-Ia1
+ cells remain obscure. Because the
TGF-b1 phenotype requires apoptosis for the develop-
ment of fibrosis and remodeling [18] we thought it likely
that the increase in CD45
+Col-Ia1
+ cells seen in this
model were caused by increases in this form of cell
death. To test this hypothesis we explored the identity
of CD45
+Col-Ia1
+ cells in a mouse model of pulmonary
fibrosis caused by transgenic overexpression of the
bioactive human TGF-b1 gene and examined whether
caspase-mediated apoptotic responses are required for
the appearance of these cells. The human relevance of
these findings was explored in studies of cultured cells
obtained from patients with multiple forms of pulmon-
ary fibrosis. Our results indicate that CD45
+Col-Ia1
+
cells recruited to the lung by TGF-b1 are enriched for
the expression of CD14 and that their appearance in the
lung requires an increase in apoptotic cell death
responses. Our data also demonstrate that CD14
+
monocytes derived from the circulation of patients with
multiple forms of lung fibrosis show robust CD34
expression and display a propensity for collagen produc-
tion that is reduced when apoptosis is blocked.
Results
Collagen-containing leukocytes are a heterogeneous cell
population
We have previously shown that inducible overexpression
of the human TGF-b1 gene results in the accumulation
of CD45
+Col-Ia1
+ cells in the murine lung [3,25]. While
this combination of markers has traditionally been con-
sidered sufficient for the identification of fibrocytes [8],
accumulating data from our group and from others indi-
cate that this combination of markers may in fact iden-
tify a heterogeneous population of cells [6,7]. Thus, in
order to better characterize the identity of TGF-b1-
recruited intrapulmonary CD45
+Col-Ia1
+ cells, TGF-b1
transgenic positive (Tg
+) and wild-type control (Tg
-)
mice received doxycycline in their drinking water for up
to 2 weeks after which they were killed and CD45
+Col-
Ia1
+ cells quantified as we have previously described
[3]. While we would have preferred to use an antibody
specific for the immature form of collagen I, such an
antibody is currently not available. Thus, detection of
the mature form of collagen was employed. These cells
were then further immunophenotyped based on their
expression of CD14 and/or CD34.
Consistent with our prior findings, CD45
+Col-Ia1
+
cells were detected in all mice, with a robust increase
seen in the TGF-b1T g
+ animals (Figure 1a-d). Further
assessment revealed that in all mice these cells displayed
variable expression of CD14 and CD34 (Figure 1e-h).
Interestingly, cells meeting classical definition of fibro-
cytes based upon the coexpression of CD34, CD45, and
Col-Ia1 in the absence of CD14, were rare in both sets
of animals and not significantly altered between groups
(Figure 2a). In contrast, when compared to Tg
- animals,
the lungs of TGF-b1T g
+ mice contained 64.8% fewer
CD45
+Col-Ia1
+ CD14
+CD34+
+ cells (P < 0.001, Figure
2b) but nearly tenfold more CD45
+Col-Ia1
+ CD14
+CD34
- cells (P <0 . 0 0 1 ,F i g u r e2 c ) .T h ea m o u n to f
CD45
+Col-Ia1
+ cells expressing neither CD14 nor CD34
(CD45
+Col-Ia1
+ CD14
-CD34
-)d i dn o td i f f e rb e t w e e n
groups (Figure 2d). These data indicate that CD45
+Col-
Ia1
+ + cells appearing in the TGF-b1-exposed lung are
primarily composed of cells that express CD14 and lack
CD34.
Caspase inhibition attenuates TGF-b1-induced apoptosis
and accumulation of CD45
+Col-Ia1
+ cells
In order to explore the role of intrapulmonary caspase
activation and apoptotic responses in the accumulation
and phenotype of CD45
+Col-Ia1
+cells, TGF-b1T g
+ and
Tg
– mice were given doxycycline in their drinking water
and randomized to receive intraperitoneal dosing of the
caspase inhibitor carbobenzoxy-valyl-alanyl-aspartyl-[O-
methyl]-fluoromethylketone (Z-VAD/fmk) for between 2
to 14 days. Mice were killed at the height of cell death,
which occurs at 48 hours in the model, and assessed for
caspase-3 activation using immunohistochemistry and
for cell death responses using terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) staining.
Consistent with our prior reports [18], caspase-3
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(Figure 3a) and assessment of TUNEL staining in the
TGF-b1T g
+ lung revealed a 79.9% reduction in cell
death responses at this timepoint (P < 0.0003, Figure 3b).
Having confirmed that caspase inhibition does indeed
reduce apoptosis in this model, we next explored its
effects on the recruitment of CD45
+Col-Ia1
+ cells. Here
we found that treatment of TGF-b1T g
+ mice with Z-
VAD/fmk reduced CD45
+Col-Ia1
+ cells by nearly ten-
fold (P < 0.0014, Figure 3c) and restored quantities of
all CD45
+Col-Ia1
+ subtypes to wild type levels. Specifi-
cally, compared to sham-treated TGF-b1T g
+ mice, the
lungs of Z/VAD-fmk treated Tg+ mice showed no
change in CD45
+Col-Ia1
+CD14
-CD34
+ cells (P = 0.14,
Figure 3d), an 85.8% reduction in CD45
+Col-Ia1
+CD14
+CD34
- cells (P < 0.001, Figure 3e), a 71.8% increase in
CD45
+Col-Ia1
+CD14
+CD34
+ cells (P < 0.001, Figure 3f),
and essentially no change in CD45
+Col-Ia1
+CD14
-
CD34
- cells (P = 0.35, Figure 3g). These data indicate
that apoptotic cell death responses regulate the appear-
ance and phenotype of CD45
+Col-Ia1
+ cells in the
TGF-b1-exposed murine lung.
Collagen-producing leucocytes accumulate independently
of alternatively activated macrophages
Our prior studies have revealed that alternatively acti-
vated (M2) macrophages regulate the development of
fibrosis [3,26]. However, the precise relationship
between fibrocytes and macrophages in the TGF-b1-
exposed lung has not been fully explored. Given the
importance of the M2 macrophage in tissue repair and
remodeling responses we thought it possible that M2
macrophages control the appearance of CD45
+Col-Ia1
+
cells in our model. In order to test this hypothesis, the
effect of caspase inhibition on CD206/MRC
+ alterna-
tively activated macrophages was assessed via flow cyto-
m e t r ya sw eh a v ep r e v i o u s l yd e s c r i b e d[ 3 ] .R e s u l t so f
these studies revealed only a trend toward reduced M2
macrophages in the Z/VAD-fmk treated mice that did
not reach statistical significance (P = 0.09, Figure 3h).
Analysis of M2-related genes such as CD206/MRC and
MSR-1 using quantitative RT-PCR confirmed these
results (P >0 . 0 5b o t hc o m p a r i s o n s ,F i g u r e3 i ) .B e c a u s e
caspase inhibition caused a profound reduction in CD45
+Col-Ia1
+ cells without a concomitant reduction in M2
macrophages, the expression of collagen by monocyte-
derived cells is unlikely to be controlled solely by accu-
mulation of M2 macrophages.
Intrapulmonary apoptosis and CD45
+Pro-Col-Ia1
+ cells
are increased in patients with lung fibrosis
We next sought to determine the human relevance of
these findings. In planning these studies we reasoned
that if collagen-production in monocytes demonstrated
a biological relationship with the development of fibrotic
lung disease, then they would be detected in multiple
forms of lung fibrosis. Thus, our murine studies were
recapitulated in lung tissue from the discarded surgical
Figure 1 Flow cytometric detection of collagen containing
monocytes in the transforming growth factor (TGF)-b1-
exposed murine lung. (a,b) Fluorescein isothiocyanate (FITC)-
detected intracellular isotype control (x axis) versus CD45-peridinin
chlorophyll protein complex (PerCP) (y axis) in (a) Tg
- and (b) Tg
+
mice. This control was used to set the negative gate for FITC in
each animal respectively. A shift in autofluorescence is seen in the
Tg
+ animals. (c,d) FITC-detected collagen (Col)-Ia1 (x axis) versus
CD45-PerCP (y axis) in (c) Tg- and (d) Tg
+ mice. An increase in
double positive cells is seen in the Tg
+ animals. (e) Phycoerythrin
(PE) -isotype control (x axis) versus CD45-anti-allophycocyanin (APC)
(y axis). This control was used to set the negative gate for PE. (f)
CD45-PE (x axis) versus APC-isotype control (y axis). This control was
used to set the negative gate for APC. (g,h) CD34 (x axis) and CD14
(y axis) on the CD45
+Col-Ia1
+ population identified in (g) Tg
- and
(h) Tg
+ mice. In contrast to Tg- mice, in which the CD45
+Col-Ia1
+
cells express CD14 and CD34 to varying degrees, the CD45
+Col-Ia1
+
cells that appear in response to TGF-b1 overexpression are almost
uniformly CD14
+, with minimal contribution of CD34
+ cells. N = 5
mice/group, images are representative of all animals.
Peng et al. Fibrogenesis & Tissue Repair 2011, 4:12
http://www.fibrogenesis.com/content/4/1/12
Page 3 of 13margins of biopsy samples from patients with histo-
pathological or clinical findings consistent with IPF or
clinical diagnosis of connective tissue disease interstitial
lung disease (CTD-ILD), or subjects with no known par-
enchymal lung disease. Immunohistochemistry per-
formed on these samples revealed increased caspase 3
cleavage in the fibrotic samples (Figure 4a, b and data
not shown) and a nearly twofold increase in TUNEL
staining in both the IPF samples and CTD-ILD samples
when compared to non-fibrotic control (P <0 . 0 5b o t h
comparisons, Figure 4c-e). Furthermore, while non-
fibrotic lungs contained relatively low numbers of CD45
+Pro-Col-Ia1
+ cells, quantities of this population were
increased nearly threefold in the samples with IPF and
CTD-ILD (P < 0.05 for both comparisons, Figure 4e).
Notably, accumulation of intrapulmonary CD45
+Pro-
Col-Ia1
+ cells did not differ between IPF and CTD-ILD
groups (Figure 4f). These data indicate that the lungs of
patients with various forms of lung fibrosis demonstrate
increased apoptosis and elevated numbers of CD45
+Pro-
Col-Ia1
+ cells.
Cultured monocytes from humans with lung fibrosis
display enhanced differentiation into fibrocytes
The pathogenesis of pulmonary fibrosis is thought to
result in part from repeated bouts of injury leading to
ongoing remodeling responses and dysregulated repair.
The finding that fibrotic lung tissue is enriched for both
apoptotic cell death responses and increased quantities
of CD45
+Pro-Col-Ia1
+ cells supports an association
between these processes. A mechanistic connection was
explored in a human lab sample routinely accessible in
clinical medicine: the peripheral blood. Here, circulating
monocytes were obtained from the peripheral blood of
patients with IPF and CTD-ILD, as well as of normal
healthy controls, and cultured under serum-containing
conditions that favor fibrocyte outgrowth [27]. Charac-
teristics of subjects are shown in Table 1. Assessment of
spindle-shaped cells, which have traditionally been con-
sidered to be fibrocytes [2,7], revealed increased out-
growth of fibrocytes in the patients with ILD (Figure 5a,
b and data not shown). Assessment of collagen expres-
sion via flow cytometry revealed that collagen expression
was augmented in the subjects with IPF and CTD-ILD
as well. Further analysis of phenotype revealed that total
percentages of CD45
+Pro-Col-Ia1
+CD14
-CD34
+ cells
were quite low in cultures from all groups (P =0 . 0 9 ,
Figure 5c). In contrast, CD45
+Pro-Col-Ia1
+CD14
+CD34
-
cells were low in healthy subjects but increased by
threefold to fourfold in the IPF and CTD-ILD samples
(P < 0.02, Figure 5d). Percentages of CD45
+Pro-Col-Ia1
+CD14
+CD34
+ cells were low in controls but even
further increased in the IPF and CTD-ILD subjects (P <
0.02, Figure 5e). Cells exhibiting expression of neither
Figure 2 Expression of cell surface markers on CD45
+ collagen (Col)-Ia1
+ cells from transforming growth factor (TGF)-b1-exposed
murine lung. (a) Quantities of CD45
+Col-Ia1
+CD14
-CD34
+ cells did not differ between the TGF-b1T g
- and Tg
+ mice. (b) CD45
+Col-Ia1
+CD14
+CD34
+ cells were significantly reduced in the TGF-b1T g
+ mice. (c) CD45
+Col-Ia1
+CD14
+CD34
- cells were significantly increased in the TGF-b1
Tg
+ mice. (d) CD45
+Col-Ia1
+CD14
-CD34
-cells did not differ between TGF-b1T g
- and TGF-b1T g
+ mice. N = 5 mice/group, images are
representative of all animals. **P < 0.01, ***P < 0.001.
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+ collagen (Col)-Ia1
+ cell
accumulation. (a) Cleaved caspase-3 immunohistochemistry (red) in TGF-b1T g
+ mice exposed to vehicle (left) or carbobenzoxy-valyl-alanyl-
aspartyl-[O-methyl]-fluoromethylketone (Z-VAD/fmk) (right). Nuclei are counterstained with hematoxylin, 40 × original magnification. A significant
reduction in cleaved (activated) caspase-3 is noted in the Z-VAD/fmk treated mice. (b,c) Z-VAD/fmk reduces terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) staining (b) and CD45
+Col-Ia1
+ cells (c) in TGF-b1T g
+ mice. (d-f) Compared to untreated mice, the
lungs of TGF-b1T g
+ treated with Z-VAD/ fmk demonstrate unchanged quantities of CD45
+Col-Ia1
+CD14
-CD34
+ cells (d), increased quantities of
CD45
+Col-Ia1
+CD14
+CD34
+cells (e), reduced quantities of CD45
+Col-Ia1
+CD14
+CD34
- cells, and unchanged quantities of CD45
+Col-Ia1
+CD14
-
CD34
- cells. (h) Accumulation of CD206/MRC
+ cells is not affected by Z-VAD/fmk. (i) TGF-b1-induced expression of the scavenger receptors MRC
(left axis) and MSR-1 (right axis) is not affected by administration of Z-VAD/fmk. N = 5 mice/group. *P < 0.05, **P < 0.01, ***P < 0.001.
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+Pro-Col-Ia1
+CD14
-CD34
-) were rare in
all subjects (P = 0.65, Figure 5f). Subgroup analysis of
the CTD-ILD samples did not reveal a difference
between disease subtypes (data not shown).
Caspase inhibition attenuates collagen production in
cultured monocytes
Finally, we determined whether caspase inhibition
affected the phenotype of cultured monocytes from
human subjects in the three groups. Cultured mono-
cytes from each group were treated with 100 mM of Z-
VAD/fmk or phosphate-buffered saline (PBS) control
and assessed for changes in apoptosis and collagen pro-
duction. Quantification of cellular apoptosis using
annexin V labeling indicated a near complete eradica-
tion of apoptosis in the Z-VAD/fmk-treated cells (Figure
6a, b). These cells included cells in the early stages of
apoptosis (as shown by single positive for annexin V in
the right lower quadrant in Figure 6a) as well as apopto-
tic cells in the process of undergoing secondary necrosis
(cells in the right upper quadrant in figure 6b). In addi-
tion, the accumulation of collagen-producing cells was
also reduced to nearly zero in all samples (Figure 6c-e).
Due to the extremely low frequency of Pro-Col-Ia1
+
cells in these samples, further phenotyping could not be
performed. These data indicate that apoptotic cell death
responses promote collagen production in human
monocytes and confirm the human relevance of our
murine findings.
Discussion
These studies provide new insight into the relationship
of collagen-producing leucocytes and fibrotic lung dis-
ease. Specifically, they demonstrate that lung-targeted
overexpression of TGF-b1 induces the intrapulmonary
accumulation of a heterogeneous population of col-
lagen-containing leucocytes, many of which express a
cell surface phenotype characteristic of monocytes but
appear to be distinct from alternatively activated macro-
phages. Furthermore, inhibition of cellular apoptosis
results in a significant reduction in all of these popula-
tions and restores the CD45
+Col-Ia
+ cell surface pheno-
t y p es e e ni nw i l d - t y p em i c e .T h eh u m a nr e l e v a n c eo f
these findings is demonstrated by recapitulation of these
results in the lungs and circulation of patients with two
separate forms of fibrotic lung disease. Taken together,
these data suggest that in the setting of apoptotic injury,
monocytes adopt a reparative program characterized by
enhanced production of collagen I.
The identity of the collagen producing leucocytes in
our study is not entirely clear at this time but based on
the robust expression of CD34 seen the cultured human
cells, these cells are likely to be fibrocytes in intermedi-
ate state of differentiation. Fibrocytes were first
described as blood-borne, fibroblast-like cells that
appeared in exudative fluid at the earliest phases of
wound repair [2]. They are considered to originate from
CD14
+ myeloid cells and coexpress collagen I, CD45,
and the progenitor marker CD34 though this latter mar-
ker is downregulated as these cells mature in situ [28].
CD34 is also lost on human fibrocytes during in vitro
culture in the setting of TGF-b1 [12] suggesting that
CD34 may be an early fibrocyte marker which is lost as
the cell matures or is activated or that, as is seen in
other settings [29,30], TGF-b1 exposure preferentially
impedes the proliferation and survival of CD34
+ cells.
Our findings support this paradigm and are consistent
with prior reports in murine models of both asthma
[28] and bleomycin induced lung fibrosis [12] showing
that CD34
+ is rapidly lost upon entry into diseased tis-
sue. Fibrocytes demonstrate a remarkably plastic pheno-
type, adopting the functional characteristics of both
macrophages and fibroblasts in response to local cues.
Thus, if the CD14
+ collagen expressing cells seen in our
model are indeed fibrocytes, it is possible that their con-
tributions to disease in this setting would include the
fibrocyte functions typically attributed to macrophages
such as cytokine and chemokine production [9], antigen
presentation [31], inflammatory cell trafficking and acti-
vation [9] and promotion of angiogenesis [32], as well as
the extracellular matrix (ECM)-producing and wound
contractile properties typically attributed to activated
myofibroblasts. Further studies investigating the role of
collagen-producing leukocytes in lung fibrosis could be
pursued in studies which live collagen-producing cells
are isolated for in vitro studies and functional analysis.
In addition, while it is assumed that these cells are pro-
ducing collagen, it remains possible that the CD14
+ cells
have engulfed collagen. This question highlights the
need for the development of high affinity antibodies that
detect the immature form of murine collagen.
It is also noteworthy that while our human findings
recapitulated much of what was seen in the mouse,
there were a number of differences. For example,
CD45
+Col-Ia1
+ cells in the TGF-b1-exposed lung were
enriched for CD14 expression in the absence of CD34.
In contrast, while the CD45
+Pro-Col-Ia1
+ cells
obtained from obtained from patients with lung disease
also expressed high levels of CD14, many of these cells
also expressed CD34. These data are could be related
to the differences in tissue compartments studied
(blood versus lung), the use of a transgenic TGF-b1
modeling system in the mouse, and/or unaccounted
for clinical factors in the patients such as age and
comorbidities. However, because we did not further
phenotype the intrapulmonary CD45
+Pro-Col-Ia1
+
cells from humans, comparison with the animal find-
ings are limited at best. The mechanistic significance
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Page 6 of 13Figure 4 Fibrotic human lungs are enriched for terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining and
CD45
+Pro-collagen (Col)-Ia1
+ cells. (a,b) Assessment of cleaved caspase 3 (brown cytoplasmic stain) on lung biopsy sample from (a) non-
fibrotic and (b) idiopathic pulmonary fibrosis (IPF) lung sample. Nuclei are counterstained with hematoxylin (60 × original magnification). An
increase in caspase cleavage is seen in the IPF lung. (c,d) TUNEL staining (black nuclear stain) performed on (c) non-fibrotic and (d) IPF lung
shows an increase in TUNEL+ nuclei in the IPF lung. Nuclei are counterstained with nuclear fast red, 40 × original magnification. (e) Compared
to non-fibrotic samples (left) TUNEL staining is increased in lungs obtained from subjects with IPF (middle) or connective tissue disease
interstitial lung disease (CTD-ILD) (right). (f) CD45
+Pro-Col-Ia1
+ cells are increased in fibrotic lungs. Top left: intracellular isotype (x axis) versus
CD45-PE (y axis) on cells obtained from a non-fibrotic lung. The diagonal morphology of the cells reflects the high inherent autofluorescence of
lung inflammatory cells. Top right: Pro-Col-Ia1- fluorescein isothiocyanate (FITC) (x axis) versus CD45-PE (y axis) on non-fibrotic lung. There is only
minimal shift past the isotype control. Bottom left: intracellular isotype (x axis) versus CD45-PE (y axis) in cells obtained from an IPF lung. Bottom
right: Pro-Col-Ia1-FITC (x axis) versus D45-PE (y axis) on IPF lung. (g) Compared to non-fibrotic subjects (n = 6) (left), detection of CD45
+Pro-Col-
Ia1
+ cells is increased in the lungs of subjects with either IPF (n = 4, middle) or CTD-ILD (n = 4, right). *P < 0.05 **P < 0.01.
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could perhaps best be examined in studies in which
these cells are subdivided based on CD34 expression
and then adoptively transferred into murine models of
experimentally induced lung fibrosis.
In our studies, the in vivo inhibition of apoptosis in
two different cell types, murine lung epithelia and
human peripheral blood monocytes, significantly
reduced the appearance CD45
+Pro-Col-Ia1
+ cells, sug-
gesting that this phenotypic change is a non-specific
response to local cell death. Additional investigation will
be required to determine why apoptosis is required for
maximal accumulation of CD45
+Col-Ia1
+ cells. Given
the well documented effects of apoptotic bodies on
monocyte biology [33,34], it is possible that the
increased production of collagen by monocytes is a
direct response to exposure to dead/dying cells as has
been previously shown in elegant studies of cultured
m u r i n em o n o c y t e s[ 3 3 ] .T h i sh y p o t h e s i si sf u r t h e rs u p -
ported by data from studies demonstrating a reduction
in CD45
+Col-Ia1
+ cells upon exposure to the short pen-
traxin serum amyloid P, which modulates monocyte
phenotypes in response to engulfment of apoptotic cells
[35,36]. It is also possible that other cell populations
such as lymphocytes or other monocyte derived cells
respond to apoptosis by increasing the secretion of solu-
ble mediators, such as semaphorin 7a [25], Stromal
Derived Factor (SDF-1) [4] and Monocyte Chemotactic
Protein-1 (MCP1) [37] that could promote the appear-
ance of fibrocytes. In addition, caspase activation itself
could induce monocyte abnormalities that lead to
enhanced production of collagen as a form of immuno-
senesence. The documentation of elevated levels of
CD45
+Col-Ia1
+ cells in the senescence associated
mouse [38], as well as in CD14
+ cells derived from aged
but otherwise healthy humans [6], supports this latter
hypothesis. Further work is needed to define the precise
relationship between caspase activation, apoptosis, and
the accumulation of CD45
+Pro-Col-Ia
+ cells in the
TGF-b1-exposed lung and in patients with pulmonary
fibrosis.
Our studies also provide novel insight into the rela-
tionship between CD45
+Col-Ia1
+ cells and CD206+
macrophages. We have previously shown that TGF-b1
induced lung fibrosis is dependent upon M2 macro-
phage accumulation [3]. In the current study we find
that apoptosis is required for the appearance of CD45
+Col-Ia cells but has a lesser effect on macrophages.
Because CD206 is a robust marker of alternative activa-
tion [39], these data suggest that accumulation of M2
macrophages alone is insufficient for the development of
TGF-b1-induced fibrosis and remodeling. When viewed
in combination, these studies support a paradigm in
which the profibrotic effects of TGF-b1r e q u i r eb o t h
alternatively activated macrophages and collagen-produ-
cing leucocytes for maximal effect. The functional con-
tributions of these populations will require further
investigation.
Conclusions
In summary, our studies demonstrate that local apopto-
tic responses potently stimulate the recruitment of col-
lagen containing leucocytes in the TGF-b1-exposed
murine lung. These CD45
+Col-Ia1
+ cells exhibit signifi-
cant phenotypic heterogeneity and appear in response to
apoptotic cell death. These effects are seen in monocytes
derived from patients with two separate forms of fibrotic
lung disease, as well as in monocytes obtained from nor-
mal controls. These findings suggest that targeting
apoptotic responses in an effort to attenuate collagen
Table 1 Characteristics of subjects
UIP/IPF, N = 7 CTD-ILD, N = 11 Controls, N = 8 P value
Age, years 74.14 ± 2.132 55.73 ± 4.673 64.25 ± 18.0 NS
Sex, female 3/7 6/11 6/8 NS
Race:
Caucasian 7 7 6
African-American 0 2 0
Asian 0 2 2
Disease subtype:
SSc-ILD (NSIP pattern based on CT scan) N/A 6/11 N/A
AMAS-UIP pattern (biopsy proven) 5/11
Known pulmonary hypertension 0/9 0/11 N/A N/A
FVC, percentage of predicted 70.86 ± 2.492 60.70 ± 4.410 N/A NS
DLCO, percentage of predicted 55.29 ± 5.643 56.82 ± 5.220 N/A N/A
AMAS = amyopathic antisynthetase syndrome; CT = computed tomography; CTD = connective tissue disease; DLCO = diffusing capacity of the lung for carbon
monoxide; FVC = forced vital capacity; IPF = idiopathic pulmonary fibrosis; ILD = interstitial lung disease; N/A = not applicable; NS = not significant; NSIP = non-
specific interstitial pneumonia; SSc = systemic sclerosis; UIP = usual interstitial pneumonia.
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Page 8 of 13Figure 5 Cultured CD45
+ Pro-collagen (Col)-Ia
+ cells obtained from patients with pulmonary fibrosis demonstrate significant
heterogeneity. (a,b) Spindle-shaped cells in cultured monocytes obtained from (a) control samples and (b) idiopathic pulmonary fibrosis (IPF)
samples. The increase in number of spindle-shaped cells is seen in suggests an increase in fibrocytes. Similar results were seen in connective
tissue disease interstitial lung disease (CTD-ILD) (data not shown). (c-f) Immunophenotyping of the cultured cells shown in (a) and (b). (c) In
contrast to CD45
+Pro-Col-Ia1
+CD34
+CD14
- cells, which are quite rare and do not differ in frequency between normal (n = 8), (c), IPF (n = 7), and
CTD-ILD (n = 11), CD45
+Pro-Col-Ia1
+CD34
-CD14
+ cells (d), as well as CD45
+Pro-Col-Ia1
+CD34
+CD14
+ cells (e) are increased in IPF and CTD-ILD
patients. CD45
+Pro-Col-Ia1
+CD34
-CD14
- cells did not differ between groups (f). Among the patients with CTD-ILD, subgroup analysis did not
detect a difference between systemic sclerosis (SSc)-ILD and amyopathic antisynthetase syndrome (AMAS) patients (data not shown). *P < 0.05
**P < 0.01 ***P < 0.001.
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Page 9 of 13Figure 6 Caspase inhibition administration attenuates apoptosis and collagen production in cultured human monocytes. (a,b) Flow
cytometric quantification of apoptosis based on annexin V (x axis) and propidium iodide (y axis) in cultured idiopathic pulmonary fibrosis (IPF)
monocytes reveals that annexin V
+ cells are reduced in the setting of Z-VAD/fmk. (c,d) Assessment of cultured connective tissue disease
interstitial lung disease (CTD-ILD) monocytes indicates that, compared to mock-treated cells, cultured monocytes fail to adopt a spindle-shaped
phenotype when treated with Z/VAD-fmk. Similar results are seen in patients with IPF (data not shown) (e) Treatment with Z-VAD/fmk
attenuates collagen production in samples from all groups. *P < 0.05, **P < 0.01, ***P < 0.001.
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Page 10 of 13production by monocytes and the accumulation of fibro-
cytes may be beneficial in diseases of lung remodeling
and aberrant repair.
Materials and methods
Transgenic mice
All mouse experiments were approved by the Yale
School of Medicine Institutional Animal Care and Use
Committee. The CC10-tTS-rtTA-TGF-b1 transgenic
mice used in this study have been described [18]. These
mice use the Clara cell 10-kDa protein (CC10) promoter
to specifically express bioactive human TGF-b1t ot h e
lung, and were backcrossed for > 10 generations onto a
C57BL/6 background [18].
Doxycycline administration
CC10-tTS-rtTA-TGF-b1 transgene positive (Tg
+)o r
their wild-type littermate controls (transgene negative,
Tg
-) aged 8-10 weeks old were given doxycycline 0.5
mg/ml in their drinking water for up to 2 weeks.
Lung inflammation
Mice were killed and bronchoalveolar lavage (BAL) per-
formed as previously described [18]. Lung inflammation
was assessed by assessing BAL samples as described pre-
viously [18].
Collagen assessment
Total right lung collagen was measured using the Sircol
Assay following manufacturer’s protocol (Biocolour,
Carrickfergus, Ireland).
Flow cytometry
Lung samples were digested for flow cytometric identifi-
cation of CD45
+ Col-Ia1
+ cells as previously described
[3]. Total viable cells were quantified using Trypan blue
staining. Collagen-producing leukocytes were detected
using CD45 surface staining (BD Pharmingen, San Jose,
CA) and intracellular staining for Col-Ia1 (Millipore,
Billerica, MI). Flow cytometric analysis of CD45
+Col-Ia1
+ cells was performed by identifying live cells based on
forward and side scatter characteristics, gating on the
CD45
+ cells, and then gating on the Col-Ia1
+ cells
within this population. Cells were then further subgated
based on their expression of CD34 and/or CD14. Per-
centages of live cells coexpressing these markers were
multiplied by total viable cell count of digested sample
to determine the absolute number of collagen contain-
ing leucocytes.
TUNEL
TUNEL was performed as previously described [3].
Caspase activation
Detection of caspase cleavage and activation using
immunohistochemistry was performed as previously
described [18].
Annexin V
Flow cytometric assessment of annexin V externalization
was performed via flow cytometry as previously
described [18].
Histological analysis
Formalin-fixed and paraffin-embedded lung sections
were stained with hematoxylin and eosin to assess gross
morphology or Mallory’s trichrome stains to visualize
collagen deposition.
Human cell isolation and culture
All studies were performed with HIC approval and writ-
ten informed consent at Yale University School of Medi-
cine. Individuals with no known medical conditions who
self-identified as healthy were included as controls.
Patients with SSc-ILD or amyopathic antisynthetase syn-
drome according to American College of Rheumatology
(ACR) criteria or IPF according to current European
Respiratory Society (ERS)/American Thoracic Society
(ATS) criteria [40] were recruited as the study group.
Exclusion criteria included concurrent diagnosis of
malignancy, pregnancy, the presence of known secondary
lung disease such as pulmonary hypertension or chronic
airway obstruction or inability (due to psychiatric or lan-
guage limitations) to provide informed consent. A total
of 30 ml of peripheral blood was drawn, peripheral blood
mononuclear cells (PBMCs) isolated via density gradient
centrifugation and CD14+ monocytes were enriched as
previously described by our group [26]. Cells were cul-
tured in 96 well plates in the presence or absence of 100
μM Z-VAD/fmk (EMD Biochemical, Los Angeles, CA).
After 10 days of culture cells were assessed qualitatively
for fibrocytes based on spindle-shaped morphology. Cells
were then harvested and assessed for CD45
+Col-Ia1
+
phenotype by fluorescence-activated cell sorting (FACS)
as previously described [6].
Flow cytometry of human cells
Antibodies against human CD45, CD34, CD14, and
appropriate isotype controls were obtained from BD
Pharmingen. Flow cytometry and cell sorting was per-
formed using a BD FACSCalibur. Data were analyzed
using Flow Jo v 7.5 software (TreeStar, Inc, Ashland,
OR). For all analyses, isotype control staining was sub-
tracted from true antibody staining to determine the
percentage of positive cells.
Peng et al. Fibrogenesis & Tissue Repair 2011, 4:12
http://www.fibrogenesis.com/content/4/1/12
Page 11 of 13Statistics
Gaussian distribution of data was determined using the
D’Agostino and Pearson omnibus normality test. Nor-
mally distributed data are expressed as means ± SEM
and assessed for significance by Student’s t test or analy-
sis of variance (ANOVA) as appropriate. Data that were
n o tn o r m a l l yd i s t r i b u t e dw e r ea s s e s s e df o rs i g n i f i c a n c e
using the Mann-Whitney U test where appropriate.
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